VYLOY is the first and only CLDN18.2-targeted treatment approved in the U.S. for adults with advanced gastric and gastroesophageal junction cancer whose tumors are CLDN18.2 positive TOKYO, Oct. 18 ...
Every day, we’re bombarded with breaking news about funding, acquisition, and other discoveries. In the flood of information, many of the compelling stories slip through the cracks and get lost. “In ...